Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by AlphaCrest Capital Management LLC

AlphaCrest Capital Management LLC trimmed its stake in shares of Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 42.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,290 shares of the medical research company’s stock after selling 9,796 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Quest Diagnostics were worth $1,767,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. lifted its stake in Quest Diagnostics by 5.8% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 11,867 shares of the medical research company’s stock valued at $1,624,000 after buying an additional 654 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Quest Diagnostics during the 1st quarter valued at about $524,000. NorthCrest Asset Manangement LLC boosted its stake in Quest Diagnostics by 515.2% during the 2nd quarter. NorthCrest Asset Manangement LLC now owns 16,013 shares of the medical research company’s stock valued at $2,129,000 after purchasing an additional 13,410 shares during the period. Kentucky Retirement Systems grew its position in Quest Diagnostics by 14.8% in the 2nd quarter. Kentucky Retirement Systems now owns 8,711 shares of the medical research company’s stock worth $1,158,000 after purchasing an additional 1,126 shares during the last quarter. Finally, Argent Trust Co increased its stake in shares of Quest Diagnostics by 1.4% in the first quarter. Argent Trust Co now owns 27,237 shares of the medical research company’s stock valued at $3,728,000 after purchasing an additional 374 shares during the period. Institutional investors own 88.87% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. William Blair restated an “outperform” rating on shares of Quest Diagnostics in a research report on Thursday, October 20th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Quest Diagnostics from $129.00 to $140.00 and gave the stock a “hold” rating in a report on Friday, October 21st. Citigroup cut shares of Quest Diagnostics from a “neutral” rating to a “sell” rating and lowered their target price for the company from $145.00 to $125.00 in a research note on Thursday, November 17th. StockNews.com cut Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, November 8th. Finally, Morgan Stanley upped their target price on Quest Diagnostics from $142.00 to $146.00 and gave the stock an “equal weight” rating in a research report on Friday, October 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $148.50.

Insider Transactions at Quest Diagnostics

In other news, Director Timothy M. Ring sold 2,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $123.39, for a total value of $246,780.00. Following the transaction, the director now owns 23,933 shares in the company, valued at approximately $2,953,092.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Michael J. Deppe sold 15,497 shares of Quest Diagnostics stock in a transaction on Wednesday, October 26th. The stock was sold at an average price of $145.00, for a total transaction of $2,247,065.00. Following the completion of the sale, the chief accounting officer now owns 32,013 shares of the company’s stock, valued at $4,641,885. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Timothy M. Ring sold 2,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $123.39, for a total value of $246,780.00. Following the completion of the transaction, the director now directly owns 23,933 shares in the company, valued at $2,953,092.87. The disclosure for this sale can be found here. Insiders sold a total of 19,497 shares of company stock valued at $2,781,965 over the last quarter. Company insiders own 1.70% of the company’s stock.

Quest Diagnostics Stock Up 1.2 %

Shares of Quest Diagnostics stock opened at $148.46 on Thursday. Quest Diagnostics Incorporated has a 12-month low of $120.40 and a 12-month high of $174.16. The firm has a market capitalization of $16.91 billion, a PE ratio of 14.60 and a beta of 1.02. The company has a quick ratio of 1.34, a current ratio of 1.46 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average is $134.89 and its 200-day moving average is $134.74.

Quest Diagnostics (NYSE:DGXGet Rating) last posted its quarterly earnings data on Thursday, October 20th. The medical research company reported $2.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.17. Quest Diagnostics had a return on equity of 21.36% and a net margin of 12.00%. The firm had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter in the previous year, the company earned $3.96 EPS. The business’s revenue for the quarter was down 10.4% compared to the same quarter last year. Equities analysts anticipate that Quest Diagnostics Incorporated will post 9.85 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Stockholders of record on Wednesday, January 18th will be issued a $0.66 dividend. The ex-dividend date is Tuesday, January 17th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.78%. Quest Diagnostics’s payout ratio is currently 25.96%.

Quest Diagnostics Company Profile

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.